APA (7th ed.) Citation

Reckweg, J. T., Leeuwen, C. J. v., Henquet, C., Amelsvoort, T. v., Theunissen, E. L., Mason, N. L., . . . Ramaekers, J. G. (2023). A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Reckweg, Johannes T., Cees J. van Leeuwen, Cécile Henquet, Therese van Amelsvoort, Eef L. Theunissen, Natasha L. Mason, Riccardo Paci, Theis H. Terwey, and Johannes G. Ramaekers. A Phase 1/2 Trial to Assess Safety and Efficacy of a Vaporized 5-methoxy-N,N-dimethyltryptamine Formulation (GH001) in Patients with Treatment-resistant Depression. Frontiers Media S.A, 2023.

MLA (9th ed.) Citation

Reckweg, Johannes T., et al. A Phase 1/2 Trial to Assess Safety and Efficacy of a Vaporized 5-methoxy-N,N-dimethyltryptamine Formulation (GH001) in Patients with Treatment-resistant Depression. Frontiers Media S.A, 2023.